Pharma R&D Fact Book, The

Summary

Executives need current and independent information to answer these and similar questions. That is why Espicom Business Intelligence - the leading provider of pharmaceutical competitive intelligence - has published The Pharma R&D Fact Book 2007.

This essential report examines the research investment and drug pipelines for 39 leading companies from Abbott and Alcon to UCB and Wyeth. A complete list of companies in the report is provided below.

Utilising daily-updated data, plus an extensive review of R&D investment, the 600+ page report contains a wealth of essential information including:

• At-a-glance bullet point summaries of key business facts and events for each company.
• Extensive analysis of R&D investment, dating back to 1997 with forecasts to 2011.
• Analysis of investment by US, European and Japanese companies .
• Research ratios by company, region and 10-year change. Company-by-company graphs showing their performance against the industry average.
• R&D pipeline and graphs for each company showing the numbers of compounds in development by stage, split by novel compounds, new indications and new formulations.
• Extensive monographs of each company's pipeline showing key data such as development status, clinical trial results, licensing and deals.

Companies covered

• Abbott
• Alcon
• Allergan
• Amgen
• Astellas Pharma
• AstraZeneca
• Bayer
• Boehringer Ingelheim
• Bristol-Myer-Squibb
• Chugai
• Daiichi Sankyo
• Dainippon Sumitomo Pharma
• Eisai Eli Lilly
• Forest Labs
• Gilead
• GlaxoSmithKline
• Johnson & Johnson
• Kyowa Hakko
• Lundbeck
• Merck & Co
• Merck KGaA
• Mitsubishi Pharma
• Novartis
• Novo Nordisk
• Nycomed Otsuka
• Pfizer
• Procter & Gamble
• Recordati
• Roche
• sanofi-aventis
• Schering-Ploug
• Shionogi
• Solvay
• Takeda
• Tanabe Seiyaku
• UCB
• Wyeth

Few issues occupy as much executive and analyst time as the productivity of the industry's research and development effort. Many forecast the impending doom of the ethical industry as we know it, citing the imbalance of patent expiries against new product launches, the absence of any real recent blockbusters and the rise of generic competition and regulatory demands.

Fundamental questions need answers

• But what is the real situation in pharma R&D?
• What is the new product launch calendar looking like?
• What are the latest clinical trial results?
• What is the status, by development phase, of companies' R&D pipelines?
• Which companies are committing most investment to their R&D effort?

Content